Why Is ATAIBECKLEY INC (ATAI) Stock Moving Today?

By the Top Tier Newswire AI Desk · July 16, 2026 at 10:49 AM ET · reviewed against 18 wire stories

ATAIBECKLEY INC (ATAI) is drawing unusual attention today. Our newswire has captured 18 stories on ATAI across 14 sources in the last 36 hours, with AI sentiment reading bullish (avg 68/100).

Why ATAI stock is moving today

Shares of AtaiBeckley Inc. (ATAI) surged over 30% in pre-market trading as the company finalized a deal to be acquired by Eli Lilly and Co (LLY). The transaction is valued at up to $3.8 billion, with an initial cash payment of $6.75 per share and additional contingent value rights tied to the success of AtaiBeckley’s pipeline. The stock opened at $7.02, a significant jump from the prior close of $5.36.

What Happened

Eli Lilly agreed to acquire AtaiBeckley, a clinical-stage biotechnology firm focused on mental health therapeutics, in a deal that includes an initial $2.8 billion in cash and up to an additional $1 billion in contingent value rights. These rights are linked to the performance of key programs in AtaiBeckley’s pipeline, including BPL-003 and VLS-01. The acquisition is part of Eli Lilly’s broader strategy to expand its mental health portfolio. The news also prompted an investigation by Halper Sadeh LLC into whether shareholders are receiving a fair deal in the proposed buyout.

What The Data Shows

Intraday data shows the stock opened with a 31.0% gap up, reaching a high of $7.25 shortly after the market opened. Volume has already reached 84.5 million shares, significantly above the 3-month average. The stock has gained 46.9% over the last 8 sessions, climbing from $4.89 to $7.19. Recent insider transactions include three sales totaling $938,000 in the last 90 days, with the most recent sale reported on July 9, 2026.

What To Watch

With the acquisition now finalized, the next key event for shareholders will be the completion of the transaction and the subsequent delisting of ATAI from the public markets. Investors should monitor the company’s progress in meeting the milestones tied to the contingent value rights.

AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Not financial advice.

ATAI by the numbers

7 sessions: +46.88%Coverage: 18 stories / 14 sourcesAI sentiment: 68/100 (bullish)Mkt cap: $1.8B52w: $2.58 to $6.75

ATAI · Jul 16 session (5-min) · +32.28% vs prior close · updated 8:50 PM ET

AI sentiment, last 36h · averaged over 18 stories · 68/100 bullish

The headlines behind the move

Story flow · 8 stories on the wire, last 36h · hover or tap a dot for the headline

13d agoFinancial TimesBULLISH 67M&A

Eli Lilly buys psychedelic biotech backed by Peter Thiel

World’s biggest drugmaker agrees to buy Ataibeckley for up to $3.8bn

13d agoMarketChameleonBULLISH 67General

ATAI Surges After Buyout Investigation: What the Halper Sadeh Probe Means for Shareholders July 16, 2026

Shares of AtaiBeckley Inc. (ATAI) leaped over 30% this morning as Halper Sadeh LLC launched an investigation into whether shareholders are getting a fair deal in the proposed buyout by Eli Lilly. Here’s what you should know about the deal terms, key details, and the potential outcomes for investors.

13d agoYahoo TopBULLISH 73M&A

AtaiBeckley to be acquired by Lilly in deal valued at up to $3.8 billion

AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) has agreed to be acquired by Eli Lilly and Co (NYSE:LLY) in a transaction valued at up to approximately $3.8 billion, with the deal adding the clinical-stage biotechnology company

13d agoWSJBULLISH 73M&A

Eli Lilly to Buy Psychedelic Firm AtaiBeckley for Initial $2.8 Billion

Eli Lilly has struck a deal to buy mental-health-focused AtaiBeckley for an initial $2.8 billion, continuing the drugmaker’s recent buying spree.

13d agoMorningstarBULLISH 68M&A

Eli Lilly to Buy AtaiBeckley for Initial $2.8 Billion — Update

The deal also includes contingent value rights worth up to an additional $1 billion, or $2.50 a share, tied to AtaiBeckley's pipeline of therapeutics for mental-health conditions, including lead program BPL-003, which is aimed at providing relief from treatment-resistant depression, Eli Lilly said.

13d agoStocktwits NewsBULLISH 73M&A

ATAI Stock Soars On Eli Lilly’s $2.8B Buyout – Why Are CMPS Shares Rising Too?

Both ATAI and CMPS stocks were among the top trending on Stocktwits in pre-market trade.

13d agoBloombergBEARISH 42General

US Stock Futures Today: AtaiBeckley, GE Aerospace, UnitedHealth

S&P 500 Index futures are down 0.2% as of 7:47 a.m. in New York. The US intensified strikes against Iran, hitting an oil tanker near the country’s main export terminal for the first time since the restart of the blockade on the Islamic Republic’s ports.

13d agoCNBCBULLISH 68M&A

Eli Lilly to buy psychedelics maker AtaiBeckley for $2.8 billion

Comprehensive up-to-date news coverage, aggregated from sources all over the world by Google News.

Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →

More on ATAI: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.

Earlier ATAI move explainers: 2026-07-21 · 2026-07-20 · 2026-07-17 · 2026-07-16